Articles
🇺🇸 AmericasExpert insights, opinion pieces, and in-depth analysis on pharmaceutical trends and FDA regulations.
FDA Approval for Pfizer's Breast Cancer Drug: Vepdegestrant
The FDA has granted approval for Pfizer and Arvinas' novel breast cancer drug, vepdegestrant. This marks a significant new treatment option for patients with advanced or metastatic HR-positive, HER2-negative breast cancer who have exhausted prior endocrine therapies.
Auvelity FDA Approval: New MDD Treatment Option
The FDA has approved Auvelity, a new oral treatment for major depressive disorder (MDD) in adults, marking a significant advancement in mental health therapeutics. Manufactured by Axsome Therapeutics, this approval offers a novel option for patients seeking relief from MDD.
FDA Scrutiny Post-Market Data: Impact on Pharma Investment Strategies
This article examines the implications of FDA scrutiny on post-market data and its influence on pharmaceutical investment strategies and drug development.
Inflation Reduction Act Pharmaceutical Impact: What You Need to Know
Learn about the Inflation Reduction Act's effects on pharmaceutical pricing, focusing on key medications like insulin and cancer therapies for Medicare patients.
COFEPRIS Drug Approvals 2026: Regulatory Modernization and Market Impact
Explore the implications of COFEPRIS drug approvals in 2026, highlighting regulatory changes and their impact on the market for key medications like XYZ for diabetes.
ANVISA Clinical Trial Changes Brazil: What You Need to Know
Learn about the recent changes to ANVISA's clinical trial regulations in Brazil and how they impact drug development for various medical indications.
ANVISA Regulatory Changes: Key Impact on Foreign Drug Manufacturers in Brazil
ANVISA's recent regulatory changes significantly affect foreign drug manufacturers in Brazil, influencing drug approvals and market strategies for key treatments.
SFDA expedited review oncology: What You Need to Know
Learn about the SFDA's expedited review for oncology drugs, including [Drug Name], designed to fast-track approvals and improve patient access to essential cancer therapies.
SAHPRA Accelerated Approval: What You Need to Know About Oncology Access
Learn how SAHPRA's Accelerated Approval is transforming oncology access, expediting vital treatments like Pembrolizumab for cancer patients in need.
African Medicines Agency impact: Harmonizing Clinical Trials in Africa
The African Medicines Agency is transforming clinical trials in Africa, streamlining processes for drug approvals and improving access to essential medicines.
Local Pharmaceutical Manufacturing South Africa: SAHPRA Policy Impact 2025
This article examines the implications of SAHPRA's 2025 policies on local pharmaceutical manufacturing in South Africa, focusing on drug accessibility and innovation.
FDA Accelerated Approval Pathway: Impact on Oncology Market Access & Pricing in 2026
This article examines how the FDA's Accelerated Approval Pathway will shape oncology market access and pricing strategies for cancer therapies in 2026.
FDA Guidance on Oncology Drugs: New Rules for Accelerated Approval
The FDA's new guidance on oncology drugs outlines updated rules for accelerated approval, impacting treatments such as Pembrolizumab for various cancers.
FDA Scrutiny of RWE: Transforming US Drug Development & Approval
This article delves into the FDA's examination of Real-World Evidence (RWE) and its transformative impact on the approval processes for drugs like XYZ for chronic pain.
ANVISA Approves New Cannabis Framework & MagicTouch Device: Market Impact
The recent ANVISA approval of a new cannabis framework and the MagicTouch device marks a significant advancement in pain management solutions in Brazil.
COFEPRIS Drug Approvals 2026: What You Need to Know
Stay informed about COFEPRIS drug approvals in 2026, featuring essential insights on innovative treatments for diabetes and hypertension.
ANVISA Clinical Trial Regulations: What Foreign Pharma Must Know in 2025
Learn essential insights on ANVISA's clinical trial regulations for 2025, crucial for foreign pharmaceutical companies navigating drug approvals in Brazil.
Decentralized Clinical Trials in LATAM: Growth, Challenges & Regulatory Insights
This article delves into the rise of decentralized clinical trials in LATAM, highlighting key growth factors, challenges faced, and essential regulatory insights.
COFEPRIS Approval Pathway: Insights on Novel Immunotherapies for Advanced Melanoma
This article delves into the COFEPRIS approval process for innovative immunotherapies targeting advanced melanoma, highlighting key insights and drug developments.
Biosimilars Growth in Brazil: Market Potential Post-ANVISA Regulatory Updates
This article delves into the market potential for biosimilars in Brazil following recent ANVISA regulatory updates, highlighting Infliximab's role in treating autoimmune conditions.